Eyeworld Supplements

5 | WHITE PAPER | JULY 2021 THERAPEUTIC POTENTIAL OF REGENER-EYES ® OPHTHALMIC SOLUTION IN THE TREATMENT OF DRY EYE DISEASE Decreases in VAS and SPEED scores in the Regener-Eyes ® -treated DED patients were doc- umented 3 months after the administration of Regener-Eyes ® , while the highest reduction in VAS and SPEED scores in these patients were ob- served after 12 months of Regener-Eyes ® -based therapy, indicating the increasingly beneficial effects of long-term use in alleviation of ocu- lar symptoms in DED patients. 12 Importantly, Regener-Eyes ® was well tolerated. None of 131 Regener-Eyes ® -treated DED patients reported any side effects related to the Regener-Eyes ® therapy, suggesting that topical application of Regener-Eyes ® is a safe and effective therapeutic approach in DED treatment. 12 Dry eye cases treated with Regener-Eyes ® (Courtesy of Marguerite McDonald, MD) Case #1, M.R. A 26-year-old female nurse presented 4 years ago with severe dry eye and epithelial basement membrane disease (EBMD) with recurrent erosion syndrome OU. She has un- dergone PTKs OU (2017 and 2019, respec- tively), though symptoms have returned, as new areas of EBMD have appeared outside the prior PTK treatment zones. She is reluc- tant to have more laser surgery, as she has already lost a lot of time to recurrent erosion episodes and fears the additional downtime will put her job at risk. M.R. had a best corrected VA of 20/25 –2 OD and 20/30 –2 OS. After being on Regener-Eyes ® Professional Strength QID OU for 4 weeks, her best corrected vision improved to 20/20 OU, and she has had no recurrent erosion symptoms. M.R. has prevent ocular surface epithelial damage in the eyes of DED patients, resulting in the possible al- leviation of dryness, grittiness, scratchiness, and soreness. 1,9,17 A topical administration of platelet-rich plas- ma eye drops that contains a large amount of PF4, epithelial growth factors, fibroblast growth factors, and vascular endothelial growth factor successfully treated moderate to severe DED. Regener-Eyes ® contains a high concentration of PF4, which may promote the repair and regen- eration of injured epithelial cells on the ocular surface. 1,9,18 Therefore, the beneficial effects of Regener-Eyes ® may be partially explained by the regenerative and protective properties of PF4. 1,9 Experimental and clinical evidence of Regener-Eyes ® -based efficacy in DED treatment We recently demonstrated that Regener-Eyes ® may protect corneal epithelial cells from chem- ical injury. 12 While cytoplasm vacuolization and swelling, accompanied by the loss of cell-to-cell contact, were observed in benzalkonium chlo- ride (BAC)-treated human corneal epithelial cells (HCEC) in vitro, these morphological and func- tional changes were not seen in BAC-treated HCEC that grew in the presence of Regener-Eyes ® . 12 Ad- ditionally, Regener-Eyes ® significantly improved viability of BAC-injured HCEC while protecting them from BAC-induced chemical injury. 12 In line with these results are findings obtained in clinical settings. 12 Regener-Eyes ® was shown to help efficiently alleviate ocular discomfort and pain in a study of 131 DED patients (27 males and 104 females with a median age of 62 years [range 19–85]) during a 12-month follow-up period. 12

• Cover